Navigation Links
Janssen Products, LP Modifies Prescribing Information for PROCRIT® (Epoetin alfa) in Chronic Kidney Disease
Date:6/24/2011

ions [see Warnings and Precautions (5.1)].

The Warnings and Precautions section highlights state that "Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit." The section advises prescribers to use caution in patients with coexistent cardiovascular disease and stroke.

The Dosage and Administration section has been revised to include additional guidance to prescribers, as follows:

In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL.  No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks.  Individualize dosing and use the lowest dose of PROCRIT sufficient to reduce the need for RBC transfusions [see Warnings and Precautions (5.1)].  Physicians and patients should weigh the possible benefits of decreasing transfusions against the increased risks of death and other serious cardiovascular adverse events [see Boxed Warning and Clinical Studies (14)].

For all patients with CKD:

When initiating or adjusting therapy, monitor hemoglobin levels at least weekly until stable, then monitor at least monthly.  When adjusting therapy consider hemoglobin rate of rise, rate of decline, ESA responsiveness and hemoglobin variability.  A single hemoglobin excursion may not require a dosing change.

  • Do not increase the dose more frequently than once every 4 weeks.  Decreases in dose can occur more frequently.  Avoid frequent dose adjustments.
  • If the hemoglobin rises rapidly (e.g., more than 1 g/dL in any 2-week period), reduce the dose of PROCRIT by 25
    '/>"/>

SOURCE Janssen Products, LP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
2. Record Breaking $327 Million Verdict Announced in Janssen Case
3. MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness
4. Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
5. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
6. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
7. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
8. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
9. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
10. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
11. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... CYBX ) today announced results for the quarter ended ... Operating results for the first quarter of fiscal ... other achievements, include: , Worldwide net product sales of ... net sales of $13.2 million, an increase of 14.5% on ... reached a new high of $58.8 million, an increase of ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium Pharmaceuticals, ... specialty biopharmaceutical company, today announced positive results from ... clostridium histolyticum (or CCH) for the treatment of ... In the Phase 2a trial, all three doses ... (0.84mg)) showed an improvement in the appearance of ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Kentucky blocked the sale of more ...
Breaking Medicine Technology:Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... genetics,(Nasdaq: DCGN ) today announced the filing ... the company,s novel small-molecule modulator,of phosphodiesterase 4 (PDE4), ... compound is being developed as a new and ... loss and cognitive deficits associated,with Alzheimer,s disease and ...
... from the,French Medicine Agency (AFSSAPS) the authorization to ... PL37, its lead compound for oral,treatment of neuropathic ... pain condition, with an estimated,prevalence in the world,s ... most,recent surveys, with many causes such as shingles, ...
Cached Medicine Technology:deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2
(Date:8/21/2014)... While golfing in Scotland and abroad, Biteback ... focused on his game due to the incessant buzzing ... and continual need to spray insect repellent became so ... from insects while golfing. He ultimately found a solution ... Banking Industry, decided to change direction and launch Biteback ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Denver ... Inspirational Sponsor for the American Lung Association in Colorado’s ... thrilled to welcome Webolutions as a sponsor,” said Curt ... Southwest, and Executive Director, American Lung Association in Colorado, ... the table in this role they’ve defined.” , Webolutions ...
(Date:8/21/2014)... HIPAA Secure Now! rolled out its EHR (electronic ... vendors to now offer their customers a HIPAA security ... , HIPAA Secure Now! provides risk analysis services, ... U.S. The company assesses the risks of storing and ... and device used by the practice. , HIPAA ...
(Date:8/21/2014)... 2014 Consilium Staffing, Your Partner in ... temporary physicians in response to the President’s landmark VA ... billion to the Department of Veterans Affairs to hire ... more than one hundred fifty medical centers nationwide, and ... of patients awaiting treatment, including vets from the Vietnam ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The employees ... Historic Park in Washington Crossing, Pennsylvania on Thursday, August ... park. “We have been looking for different ways that ... Matt Kiernan, Partner with Pharmica Consulting. “When we heard ... of U.S. history, we jumped at the opportunity.” , ...
Breaking Medicine News(10 mins):Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3Health News:HIPAA Secure Now! Ramps up EHR Partner Program, Helps Healthcare Providers Achieve Meaningful Use under Revised CMS Deadlines 2Health News:Consilium Staffing Providing Locum Tenens in Response to VA Hospital Reform Legislation 2Health News:Pharmica Spends the Day Helping to Preserve Washington Crossing Historic Park 2
... PUA Forums.com, the ... meet and charm women, is now also helping men take it to the next level - ... ... for dating advice that has already helped thousands of men learn how to meet and charm ...
... ... the rage. Today more than ever, people are turning to books on attaining success to ... lumped together, a recent discovery by Steve Paris, CEO of Orne Publishing, is about to turn ... , ...
... , ... days in June, QuickMedical® converted their 11,000 square foot warehouse into a showcase for ... of free food and prizes, the QuickMedical® Open House and Benefit was an event ... ...
... ... web portal that provides a comprehensive view of California public policy and legislative issues. ... tracking in one site. , ... (PRWEB) June 28, 2010 -- The ‘LegisWeb Eye’ launches on July 1st, bringing a new ...
... lower their cholesterol are 30 percent less likely to see ... who do not use the drugs, according to researchers at ... of the drugs were associated with lower risk of recurrence. ... "The findings add another layer of evidence ...
... , SUNDAY, June 27 (HealthDay News) -- Scientists have located ... predisposition for type 2 diabetes, bringing the total number of ... At this point, the findings don,t mean much for patients ... treatments. "From here, to apply this clinically is going ...
Cached Medicine News:Health News:PUA Forums Will Help You Get A Girlfriend 2Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 2Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 3Health News:QuickMedical Open House and Benefit for Seattle Children's Hospital A Resounding Success 2Health News:QuickMedical Open House and Benefit for Seattle Children's Hospital A Resounding Success 3Health News:The 'LegisWeb Eye' Legislative Web Portal Launches on July 1st 2Health News:The 'LegisWeb Eye' Legislative Web Portal Launches on July 1st 3Health News:Statins associated with lower cancer recurrence following prostatectomy 2Health News:More Genes Implicated in Type 2 Diabetes 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: